HDAC6 and Miyoshi myopathy: This mechanism of protein clearance is thought to be responsible for the resistance to proteasome inhibitors in MM patients, and preclinical studies have shown that HDAC6 inhibitors induced synergistic anti-tumor activity with bortezomib in bortezomib-resistant cell models [15, 16].